Teladoc Health Reports Third-Quarter 2020 Results

Rhea-AI Summary

Teladoc Health reported impressive financial results for Q3 2020, with revenue surging 109% year-over-year to $288.8 million, and total visits increasing 206% to 2.8 million. For the first nine months, revenue grew 79% to $710.6 million. The company raised its full-year guidance, expecting total revenue of $1,005 million to $1,015 million. Despite a net loss of $(35.9) million, excluding merger-related costs, adjusted EBITDA reached $39.5 million. Strong growth in memberships and partnerships with firms like Johns Hopkins bolster future prospects.

Positive

• Q3 revenue increased 109% YoY to $288.8 million.
• Total visits surged 206% to 2.8 million.
• Nine-month revenue rose 79% to $710.6 million.
• Adjusted EBITDA improved to $39.5 million from $9 million YoY.
• Raised full-year revenue guidance to $1,005 million - $1,015 million.

Negative

• Net loss for Q3 was $(35.9) million, up from $(20.3) million YoY.
• GAAP gross margin decreased to 63.3% from 68.1% YoY.

Year-over-year Q3 revenue grows 109% to $288.8 million and total visits increase 206% to 2.8 million

Year-over-year nine months revenue grows 79% to $710.6 million and total visits increase 163% to 7.6 million

Issues 2020 fourth-quarter guidance, raises full-year expectations

PURCHASE, N.Y., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today reported strong financial results for the quarter ending September 30, 2020.

“Our strong third quarter results exceeded expectations, driven by broad-based strength across the business and building on the momentum we saw in the first half of the year,” commented Jason Gorevic, chief executive officer of Teladoc Health. “We are seeing significant market success and consistent growth in member visits throughout all of our commercial channels. With the addition of Livongo later this year, we will be creating a new category of whole person virtual care that will transform how people live healthier lives.”

Teladoc Health recently entered new and expanded client partnerships with industry leaders including GuideWell, Johns Hopkins and Telefonica. The company highlighted continued, sustainable growth bolstered by increases in specialty visits and registrations together with ongoing diversity of visit diagnoses.

Financial Highlights for the Third Quarter and Nine Months Ended September 30, 2020

Revenue
($ thousands)
		Quarter Ended						Year over Year				Nine Months Ended						Year over Year
		September 30,						Growth				September 30,						Growth
		2020			2019							2020			2019
Access Fees Revenue
U.S.		$	194,622		$	92,095		111		%		$	454,582		$	258,604		76		%
International			31,997			27,030		18		%			91,261			77,716		17		%
Total			226,619			119,125		90		%			545,843			336,320		62		%
Visit Fee Revenue
U.S. Paid Visits			35,074			14,142		148		%			105,013			47,473		121		%
U.S. Visit Fee Only			15,874			4,307		269		%			47,931			11,974		300		%
International Paid Visits			96			395		(76	)	%			705			1,051		(33	)	%
Total			51,044			18,844		171		%			153,649			60,498		154		%
Other
U.S.			10,299			0		N/M		%			10,299			0		N/M		%
International			850			0		N/M		%			850			0		N/M		%
Total			11,149			0		N/M		%			11,149			0		N/M		%
Total Revenue		$	288,812		$	137,969		109		%		$	710,641		$	396,818		79		%

Membership and Visit Fee Only Access
(millions except for care locations)
		Quarter Ended				Year over Year
		September 30,				Growth
		2020		2019
Total U.S. Paid Membership		51.5		35.0		47	%
Total U.S. Visit Fee Only Access		21.8		19.0		15	%

Visits
(thousands)
		Quarter Ended								Year over Year				Nine Months Ended							Year over Year
		September 30,								Growth				September 30,							Growth
		2020				2019								2020				2019
Paid Visits from U.S. Paid Membership		682				278				145	%			2,127				934			128	%
Percent of Paid Visits from U.S. Paid Membership		32		%		45		%						39		%		48		%
Visits Included from U.S. Paid Membership		1,447				344				321	%			3,384				1,016			233	%
Total Visits from U.S. Paid Membership		2,129				622				242	%			5,511				1,950			183	%
U.S. Visit Fee Only		261				62				318	%			794				179			343	%
International Visits		445				244				83	%			1,331				770			73	%
Total Visits		2,835				928				206	%			7,636				2,899			163	%
Utilization		16.5	%			8.0	%			854	pt			15.4	%			9.3	%		615	pt
Platform-Enabled Sessions*		986				-				N/M	%			-				-			N/M	%

* Platform-Enabled Session is a unique instance in which our licensed software platform has facilitated a virtual voice or video encounter between a care provider and our client’s patient, or between care providers. We believe platform enabled sessions are an indicator of the value our clients derive from the platform they license from us in order to facilitate virtual care.

• Net loss was $(35.9) million for the third quarter 2020 compared to $(20.3) million for the third quarter 2019. Excluding $16.0 million of transaction costs related to the pending Livongo merger, net loss was $(19.9) million for the third quarter of 2020. Excluding $25.2 million of transaction costs related to the pending Livongo merger and the acquisition of InTouch Health, which closed on July 1^st, net loss was $(10.7) million for the third quarter of 2020.
• Net loss per basic and diluted share was $(0.43) for the third quarter 2020 compared to $(0.28) for the third quarter 2019. Excluding transaction costs of $0.19 per share related to the pending Livongo merger, net loss per share was $(0.24). Excluding transaction costs of $0.30 per share related to the pending Livongo merger and the acquisition of InTouch Health, which closed on July 1^st, net loss per share was $(0.13) for the third quarter of 2020.
• GAAP Gross margin which includes depreciation and amortization was 63.3 percent for the third quarter 2020 and 68.1 percent for the third quarter 2019.
• Adjusted Gross margin was 63.7 percent for the third quarter 2020 compared to 69.0 percent for the third quarter 2019.
• EBITDA was a loss of $(6.8) million for the third quarter 2020 compared to a loss of $(10.3) million for the third quarter 2019. Excluding $16.0 million of transaction costs related to the pending Livongo merger, EBITDA was $9.2 million. Excluding $25.2 million of transaction costs related to the pending Livongo merger and the acquisition of InTouch Health, which closed on July 1^st, EBITDA was $18.4 million for the third quarter of 2020.
• Adjusted EBITDA was a positive $39.5 million for the third quarter 2020 compared to a positive $9.0 million for the third quarter 2019.

A reconciliation of generally accepted accounting principles (“GAAP”) in the United States to non-GAAP results has been provided in this press release in the accompanying tables. An explanation of these measures is also included below under the heading “Non-GAAP Financial Measures”.

Financial Outlook
Teladoc Health provides guidance based on current market conditions and expectations. Given the uncertainty of the expected path of the COVID-19 outbreak as well as the broader economic impact, our updated guidance is based on what we know today. As this is an emerging situation, circumstances are likely to change in the coming weeks and months, but we believe our guidance ranges provide a reasonable baseline for 2020 financial performance.

For the fourth-quarter 2020, we expect:

• Total revenue to be in the range of $294 million to $304 million.
• EBITDA (loss), excluding transaction costs related to the pending Livongo merger, to be in the range of $(1) million to $2 million.
• Adjusted EBITDA to be in the range of $21 million to $24 million.
• Total U.S. paid membership to be in the range of 50 million to 51 million members and visit-fee-only access to be available to 21 to 22 million individuals, including 2 to 3 million members on a temporary basis.
• Total visits to be between 2.8 million and 3.0 million.
• Net loss per share, excluding all transaction costs related to the pending Livongo merger, based on 84.4 million weighted average shares outstanding, to be between $(0.36) and $(0.33).

For the full-year 2020, we expect:

• Total revenue to be in the range of $1,005 million to $1,015 million.
• EBITDA (loss), excluding all transaction costs related to the pending Livongo merger, to be in the range of $(1) million to $2 million.
• Adjusted EBITDA to be in the range of $97 million to $100 million.
• Total U.S. paid membership to be in the range of 50 million to 51 million members and visit-fee-only access to be available to 21 to 22 million individuals, including 2 to 3 million members on a temporary basis.
• Total visits to be between 10.4 million to 10.6 million.
• Net loss per share, excluding all transaction costs related to the pending Livongo merger, based on 79.4 million weighted average shares outstanding, to be between $(1.36) and $(1.32).

Quarterly Conference Call

The third quarter 2020 earnings conference call and webcast will be held Wednesday, October 28, 2020 at 4:30 p.m. EDT. The conference call can be accessed by dialing 1-888-869-1189 for U.S. participants, or 1-706-643-5902 for international participants, and including the following Conference ID Number: 2684889 to expedite caller registration; or via a live audio webcast available online at http://ir.teladoc.com/news-and-events/events-and-presentations/. A webcast replay will be available for on-demand listening shortly after the completion of the call at the same web link.

About Teladoc Health

Teladoc Health is transforming how people access and experience healthcare. Recognized as the world leader in virtual care, Teladoc Health directly delivers millions of medical visits across 175 countries each year through the Teladoc Health Medical Group and enables millions of patient and provider touchpoints for thousands of hospitals, health systems and physician practices globally. Ranked Best in KLAS for Virtual Care Platforms in 2020, Teladoc Health leverages more than a decade of expertise and real-time insights to meet the growing virtual care needs of consumers, healthcare professionals, employers and health plans. For more information, please visit www.teladochealth.com or follow @TeladocHealth on Twitter.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “believe,” “project,” “estimate,” “expect,” “may,” “should,” “will” and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding future revenues, future earnings, future numbers of members or clients, litigation outcomes, regulatory developments, market developments, new products and growth strategies, and the effects of any of the foregoing on our future results of operations or financial conditions.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) changes in laws and regulations applicable to our business model; (ii) changes in market conditions and receptivity to our services and offerings; (iii) results of litigation; (iv) the loss of one or more key clients; and (v) changes to our abilities to recruit and retain qualified providers into our network. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our SEC reports, including, but not limited to our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as filed with the SEC.

Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share data, unaudited)

		September 30,				December 31,
		2020				2019
Assets
Current assets:
Cash and cash equivalents		$	1,187,299			$	514,353
Short-term investments			3,070				2,711
Accounts receivable, net of allowance of $4,661 and $3,787, respectively			85,803				56,948
Inventories			11,578				0
Prepaid expenses and other current assets			22,293				13,990
Total current assets			1,310,043				588,002
Property and equipment, net			20,364				10,296
Goodwill			1,691,355				746,079
Intangible assets, net			386,573				225,453
Operating lease - right-of-use assets			33,933				26,452
Other assets			7,117				6,545
Total assets		$	3,449,385			$	1,602,827
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable		$	21,408			$	9,075
Accrued expenses and other current liabilities			65,130				34,439
Accrued compensation			53,957				34,201
Deferred revenue-current			46,721				12,466
Advances from financing companies			13,609				0
Total current liabilities			200,825				90,181
Other liabilities			1,033				9,239
Operating lease liabilities, net of current portion			30,326				24,994
Deferred revenue, net of current portion			4,884				2,300
Advances from financing companies, net of current portion			9,901				0
Deferred taxes			17,896				21,678
Convertible senior notes, net			953,484				440,410
Commitments and contingencies
Stockholders’ equity:
Common stock, $0.001 par value; 150,000,000 shares authorized as of September 30, 2020 and December 31, 2019; 84,358,345 shares and 72,761,941 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively			84				73
Additional paid-in capital			2,835,274				1,538,716
Accumulated deficit			(598,694	)			(507,525	)
Accumulated other comprehensive loss			(5,628	)			(17,239	)
Total stockholders’ equity			2,231,036				1,014,025
Total liabilities and stockholders’ equity		$	3,449,385			$	1,602,827

CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except share and per share data, unaudited)

		Quarter Ended September 30,								Nine Months Ended September 30,
		2020				2019				2020				2019
Revenue		$	288,812			$	137,969			$	710,641			$	396,818
Expenses:
Cost of revenue  (exclusive of depreciation and amortization shown separately below)			104,725				42,799				267,887				129,110
Operating expenses:
Advertising and marketing			52,302				31,321				132,395				84,341
Sales			23,483				16,120				60,110				48,164
Technology and development			29,958				15,746				72,244				48,398
Legal and regulatory			2,812				1,634				6,266				5,239
Acquisition and integration related costs			25,395				1,995				30,686				4,143
General and administrative			56,930				38,681				156,433				113,212
Depreciation and amortization			12,932				9,617				32,535				29,065
Total expenses			308,537				157,913				758,556				461,672
Loss from operations			(19,725	)			(19,944	)			(47,915	)			(64,854	)
Loss on extinguishment of debt			1,227				0				8,978				0
Interest expense, net			17,222				7,700				39,676				21,432
Net loss before taxes			(38,174	)			(27,644	)			(96,569	)			(86,286	)
Income tax (benefit) expense			(2,290	)			(7,298	)			(5,400	)			(6,466	)
Net loss		$	(35,884	)		$	(20,346	)		$	(91,169	)		$	(79,820	)
Net loss per share, basic and diluted		$	(0.43	)		$	(0.28	)		$	(1.17	)		$	(1.11	)
Weighted-average shares used to compute basic and diluted net loss per share			83,607,902				72,151,094				77,821,073				71,601,790

CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands, unaudited)

		Nine Months Ended September 30,
		2020				2019
Cash flows used in operating activities:
Net loss		$	(91,169	)		$	(79,820	)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization			38,029				33,860
Allowance for doubtful accounts			2,320				1,717
Stock-based compensation			61,151				48,245
Deferred income taxes			(4,096	)			(10,288	)
Accretion of interest			29,459				19,422
Loss on extinguishment of debt			8,978				0
Changes in operating assets and liabilities:
Accounts receivable			(16,450	)			(12,386	)
Prepaid expenses and other current assets			(5,906	)			(2,219	)
Inventory			(2,392	)			0
Other assets			140				73
Accounts payable			6,584				(1,976	)
Accrued expenses and other current liabilities			17,269				14,304
Accrued compensation			9,329				(1,813	)
Deferred Revenue			15,348				6,708
Operating lease liabilities			(4,360	)			(1,481	)
Other liabilities			(2,809	)			(2,599	)
Net cash provided by operating activities			61,425				11,747
Cash flows (used in) provided by investing activities:
Purchase of property and equipment			(2,872	)			(2,847	)
Purchase of internal-use software			(14,515	)			(4,658	)
Proceeds from marketable securities			0				39,165
Sale of assets			0				10
Investment in securities			(0	)			(5,000	)
Acquisition of business, net of cash acquired			(159,663	)			(11,204	)
Net cash (used in) provided by investing activities			(177,050	)			15,466
Cash flows provided by financing activities:
Net proceeds from the exercise of stock options			40,627				24,820
Proceeds from issuance of 2027 Notes			1,000,000				0
Issuance costs of 2027 Notes			(24,070	)			0
Repurchase of 2022 Notes			(228,153	)			0
Proceeds from advances from financing companies			1,924				0
Payment from customers against advances from financing companies			(4,427	)			0
Proceeds from employee stock purchase plan			2,473				1,875
Cash received (paid) for withholding taxes on stock-based compensation, net			326				(1,642	)
Net cash provided by financing activities			788,700				25,053
Net increase in cash and cash equivalents			673,075				52,266
Foreign exchange difference			(129	)			(1,013	)
Cash and cash equivalents at beginning of the period			514,353				423,989
Cash and cash equivalents at end of the period		$	1,187,299			$	475,242
Income taxes paid		$	786			$	846
Interest paid		$	5,612			$	6,112

Non-GAAP Financial Measures:

To supplement our financial information presented in accordance with generally accepted accounting principles in the United States, or U.S. GAAP, we use adjusted gross profit, adjusted gross margin, EBITDA income (loss) and adjusted EBITDA income (loss), which are non-U.S. GAAP financial measures to clarify and enhance an understanding of past performance. We believe that the presentation of these financial measures enhances an investor’s understanding of our financial performance. We further believe that these financial measures are useful financial metrics to assess our operating performance from period-to-period by excluding certain items that we believe are not representative of our core business. We use certain financial measures for business planning purposes and in measuring our performance relative to that of our competitors. We utilize adjusted EBITDA as the primary measure of our performance.

Adjusted gross profit is our total revenue minus our total cost of revenue (exclusive of depreciation and amortization shown separately) and adjusted gross margin is adjusted gross profit as a percentage of our total revenue. We believe that it provides investors meaningful information to understand our results of operations and the ability to analyze financial and business trends on a period-to-period basis.

EBITDA consists of net loss before interest, foreign exchange gain or loss, taxes, loss on extinguishment of debt, depreciation and amortization. We believe that making such adjustment provides investors meaningful information to understand our results of operations and the ability to analyze financial and business trends on a period-to-period basis.

Adjusted EBITDA consists of net loss before interest, foreign exchange gain or loss, taxes, loss on extinguishment of debt, depreciation, amortization, stock-based compensation and acquisition and integration related costs. We believe that making such adjustment provides investors meaningful information to understand our results of operations and the ability to analyze financial and business trends on a period-to-period basis.

We believe the above financial measures are commonly used by investors to evaluate our performance and that of our competitors. However, our use of the term adjusted gross profit, adjusted gross margin, EBITDA and adjusted EBITDA may vary from that of others in our industry. Neither adjusted gross profit, adjusted gross margin, EBITDA nor adjusted EBITDA should be considered as an alternative to net loss before taxes, net loss, loss per share or any other performance measures derived in accordance with U.S. GAAP as measures of performance.

Adjusted gross profit, adjusted gross margin, EBITDA and adjusted EBITDA have important limitation as analytical tools and you should not consider them in isolation or as a substitute for analysis of our results as reported under U.S. GAAP. Some of these limitations are:

• Adjusted gross margin has been and will continue to be affected by a number of factors, including the fees we charge our Clients, the number of visits and cases we complete the costs paid to Providers and medical experts as well as the costs of our provider network operations center;

• Adjusted gross margin does not reflect the significant depreciation and amortization to cost of revenue;

• EBITDA and adjusted EBITDA do not reflect the significant interest expense on our debt;

• EBITDA and adjusted EBITDA eliminate the impact of income taxes on our results of operations;

• EBITDA and Adjusted EBITDA do not reflect the loss on extinguishment of debt;

• Adjusted EBITDA does not reflect the significant acquisition and integration related costs related to mergers and acquisitions;

• Adjusted EBITDA does not reflect the significant non-cash stock compensation expense which should be viewed as a component of recurring operating costs; and

• other companies in our industry may calculate adjusted gross profit, adjusted gross margin, EBITDA and adjusted EBITDA differently than we do, limiting the usefulness of adjusted gross profit, adjusted gross margin, EBITDA and adjusted EBITDA as comparative measures.

In addition, although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and adjusted gross profit, adjusted gross margin, EBITDA and Adjusted EBITDA do not reflect any expenditures for such replacements.

We compensate for these limitations by using adjusted gross profit, adjusted gross margin, EBITDA and adjusted EBITDA along with other comparative tools, together with U.S. GAAP measurements, to assist in the evaluation of operating performance. Such U.S. GAAP measurements include net loss, net loss per share and other performance measures.

In evaluating these financial measures, you should be aware that in the future we may incur expenses similar to those eliminated in this presentation. Our presentation of adjusted gross profit, adjusted gross margin, EBITDA and adjusted EBITDA should not be construed as an inference that our future results will be unaffected by unusual or nonrecurring items.

The following is a reconciliation of gross profit, the most directly comparable GAAP financial measure, to adjusted gross profit:

Reconciliation of GAAP Gross Profit to Adjusted Gross Profit and Adjusted Gross Margin
(In thousands, unaudited)

		Quarter Ended								Nine Months Ended
		September 30,								September 30,
		2020				2019				2020				2019
Revenue		$	288,812			$	137,969			$	710,641			$	396,818
Cost of revenue (exclusive of depreciation and amortization shown separately below)			(104,725	)			(42,799	)			(267,887	)			(129,110	)
Depreciation and amortization of intangible assets			(1,149	)			(1,187	)			(4,078	)			(3,279	)
Gross Profit			182,938				93,983				438,676				264,429
Depreciation and amortization of intangible assets			1,149				1,187				4,078				3,279
Adjusted gross profit		$	184,087			$	95,170			$	442,754			$	267,708
Gross margin			63.3		%		68.1		%		61.7		%		66.6		%
Adjusted gross margin			63.7		%		69.0		%		62.3		%		67.5		%

Reconciliation of EBITDA and Adjusted EBITDA to Net Loss
(In thousands, unaudited)

		Quarter Ended								Nine Months Ended
		September 30,								September 30,
		2020				2019				2020				2019
Net loss		$	(35,884	)		$	(20,346	)		$	(91,169	)		$	(79,820	)
Add:
Loss on extinguishment of debt			1,227				0				8,978				0
Interest expense, net			17,222				7,700				39,676				21,432
Income tax benefit			(2,290	)			(7,298	)			(5,400	)			(6,466	)
Depreciation expense			1,272				982				2,983				2,701
Amortization expense			11,660				8,635				29,552				26,364
EBITDA			(6,793	)			(10,327	)			(15,380	)			(35,789	)
Stock-based compensation			20,908				17,354				61,151				48,245
Acquisition and integration related costs			25,395				1,995				30,686				4,143
Adjusted EBITDA		$	39,510			$	9,022			$	76,457			$	16,599

FAQ

What is Teladoc's revenue growth for Q3 2020?

Teladoc reported a revenue growth of 109% year-over-year for Q3 2020, reaching $288.8 million.

How many total visits did Teladoc report in Q3 2020?

Teladoc reported a total of 2.8 million visits in Q3 2020, a 206% increase year-over-year.

What is the guidance for Teladoc's full-year 2020 revenue?

Teladoc expects its full-year 2020 revenue to be between $1,005 million and $1,015 million.

Did Teladoc experience a net loss in Q3 2020?

Yes, Teladoc experienced a net loss of $(35.9) million in Q3 2020.

What partnerships did Teladoc announce recently?

Teladoc expanded partnerships with industry leaders including GuideWell, Johns Hopkins, and Telefonica.